This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Spectrum Pharmaceuticals, Inc.

Drug Names(s): PDX, 10-Propargyl-10-Deazaaminopterin, Pralatrexate

Description: PDX is a small-molecule cytotoxic agent that inhibits the enzyme dihydrofolate reductase (DHFR). DHFR is a key enzyme required for the maintenance of adequate intracellular reduced folate levels. PDX and other inhibitors of DHRF, such as methotrexate are commonly known as antifolates. PDF is an improved version of methotrexates, with superior efficacy and toxicity profile. Inhibition of DHFR prevents the formation of tetra-hydrofolates that are essential in the biosynthesis of thymidylate and purine nucleotide precursors for DNA synthesis.

Antifolates, such as methotrexate, were one of the earliest classes of drugs developed for clinical use in cancer chemotherapy. Today, methotrexate is still used extensively in the treatment of human leukemia, breast cancer, head and neck cancer, choriocarcinoma, osteosarcoma, and lymphoma. Antifolate compounds also have important clinical utility outside the realm of oncology, in the treatment of such diverse diseases as rheumatoid arthritis, psoriasis, bacterial and plasmodial infections, and opportunistic infections associated with AIDS.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

In December 2002, Allos obtained an exclusive worldwide license from Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute to intellectual property covering PDX.

Allos has acknowledged an 8% royalty due to the third parties involved in PDX development and for associated intellectual property.

Allos and Idis
In December 2009, Allos Therapeutics announced the execution of a collaborative agreement with Idis to manage the named patient program to provide access to Folotyn for patients with relapsed or refractory peripheral T-cell lymphoma outside of the United States. Allos retains exclusive worldwide rights to develop and commercialize Folotyn in all indications.

Allos and Mundipharma
In May 2011, Allos and Mundipharma entered into a strategic collaboration agreement to co-develop Folotyn. Under the agreement, Allos retains full commercialization...See full deal structure in Biomedtracker

Partners: Clinigen Group plc Mundipharma International Limited

Folotyn News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug